RANI News and Press, Rani Therapeutics Holdings Inc. From 08/10/22

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) --...

- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events - - Bioavailability of PTH delivered via the RaniPill was found to be 300-400% greater than PTH delivered via subcutaneous injection - - Improved RaniPill design enabled 95% drug deliv...

Rani Therapeutics ( NASDAQ: RANI ) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’...

SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it has entered into a loa...

Rani Therapeutics press release (NASDAQ:RANI): Q1 GAAP EPS of -$0.29 beats by $0.03. Cash and cash equivalents of $107.84M For further details see: Rani Therapeutics GAAP EPS of -$0.29 beats by $0.03

- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill ™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board with the appointment of Lisa Rometty - SAN JOSE,...

SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief...

SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- The winners of Fast Company ’s 2022 World Changing Ideas Awards were announced today, with Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), earning the top honors in the...

SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chi...

Rani Therapeutics Holdings, Inc. (RANI) Q4 2021 Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group LLC Talat Imran - CEO Svai Sanford - Chief Financial Officer Mir Hashim - Chief Scientific Officer Conference Call Part...